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Synthesis of the Chloroketones Ac-Ala-Ala-Ala-AlaCH aC] and 
Ac-Ala -Ala- Pro -AlaCH 2-  Cl. As of Aug 31, 1974, the synthesis 
of Ac-Ala-Ala-Pro-AlaCH
2
C1 has been carried out once on a small 
scale (yield 200mg) and once on a large scale (yield 4-6g) by 
James Boone (a postdoctorial fellow who started the synthesis on 
June 15, 1974). The product from the large scale reaction has 
not yet been purified and crystalized. Many of the synthetic in-
termediates have been prepared in large amounts and in particular 
Ac-Ala-Ala-OH and Z-AlaCH 2 Cl will be used in the synthesis of the 
second chloroketone, Ac-Ala-Ala-Ala-AlaCH 2 C1. 
Distribution of Inhibitors. A summary of the requests for 
inhibitors prepared by Dr. Clark Lum (letter of Aug. 19, 1974) 
indicates an initial need for 0.5g of each chloromethyl ketone 
inhibitor. We have on hand 0.5g of Ac-Ala-Ala-Ala-AlaCH 2 Cl from 
an earlier synthesis. We expect to have Ac -Ala -Ala- Pro -AlaCH 2 CL 
purified and crystalized next week. We will therefore begin to 
mail out the inhibitors next week. I will contact Dr. Clark by 
phone to discuss details of the shipping. 
Study of the Inhibition of Leukocyte Elastase. A study of 
the rate of reaction of human leukocyte elastase (1.6mg kindly 
provided to us by Dr. Aaron Janoff at the State University of 
New York, Stony Brook) at pH 6.5 with 10 chloromethyl ketones 
has been completed ( a preprint of a manuscript detailing our 
results is attached). The most effective inhibitor was Ac-Ala-
Ala-Pro-MaCH 2
C1(relative rate 15.8 compared to that of Ac-Ala-
Ala-AlaCH 2
Cl which was 1.0). Other relative inhibitors were 
Z - Gly - Leu-AlaCH 2 C1 (7.3) and Ac-Ala-Pro-Ala-AlaCH 2 C1 (8.1). 
Ac-Ala-Ala-Ala-AlaCii 2
C1 had a relative rate of 3.5. 
Synthesis of Other Elastase Inhibitors. Mr. David Carroll 
has recently synthesized the carbozate Z-Ala-Ala-Pro-NH-N-00-0Np 
N 3 
This irreversibly acylated porcine elastase. Preliminary ex-
periments with human leukocyte elastase (before we ran out of 
enzyme) indicate that this compound is also an effective inhibitor 
of the human enzyme. We are pursuing synthesis and enzymatic 
studies with this new class of elastase inhibitors. 
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Several proteolytic enzymes are known to occur in human polymorpho-
nuclear (PMN) leukocyte granule fractions, including an elastase that is active 
at physiologic pH.' -4 The human leukocyte elastase has been isolated and puri-
fied by affinity chromatography. It is known to degrade human lung elastin, 
arterial walls, and basement membrane, digest proteins of bacterial cell walls 
in vitro, induce cellular surface changes correlated with loss of growth control, 
and undergo inhibition by a 1 -antitrypsin and peptide chloromethyl ketones. 5-9 
A growing body of experimental evidence has suggested that this elastase may 
be involved in pathologic processes associated with elastic tissue damage in 
acute arthritis, pulmonary emphysema, and related diseases. 10-13 Thus, synthetic 
elastase inhibitors would be expected to be useful reagents both for the treat-
ment of arthritis, emphysema, and related diseases and for the study of the 
biologic function of elastolytic enzymes. 
Human leukocyte elastase is similar to the more widely studied porcine 
pancreatic elastase 14 in many respects. They are both serine proteases and 
show esterase activity toward synthetic substrates, such as Boc-Ala-ONp and 
Ac-Ala-Ala-Ala-OCH 3 . 
One very useful class of inhibitors for serine proteases is the chloromethyl 
ketones. These inhibitors, if properly designed to resemble a substrate, are 
fairly specific for one serine protease or a group of serine proteases with similar 
specificities. 15 The reason for this specificity is apparent upon consideration of 
the mechanism of action of serine proteases. A substrate is bound in such a 
way that the carbonyl group of the scissile peptide bond is properly oriented 
to be attacked by the active-site serine residue, which action leads to an acyl 
enzyme intermediate that rapidly turns over (FIGURE 1). A similarly bound 
chloromethyl ketone inhibitor (FIGURE 1), however, would place the active-site 
histidine residue next to the alkylating group of the inhibitor, which results in 
the formation of a covalent bond between enzyme and inhibitor. Attack by 
the active-site serine residue on the carbonyl group of the inhibitor would lead 
to no stable products. 
A series of alanine tri- and tetrapeptide chloromethyl ketones was recently 
synthesized by us 14 ' IT and subsequently by two independent groups 18 . 1!  as 
elastase inhibitors. The inhibitors were designed to contain two features thought 
to be essential for effective inhibition, a terminal alanine chloromethyl ketone 
moiety due to the known specificity of elastase and an extended peptide chain, 
because the rate of elastase hydrolysis of synthetic substrates is strongly 
• Supported by a Research Corporation grant and by National Institutes of Health 
Grant GM-18292 and Contract HR-42939. 
t Recipient of NDEA Traineeship Funds (1972-1974). 
420 
Reprint ed from 
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES 
Volume 256, Pages 420-425 
June 13, 1975 
y. 
Powers et al.: Elastolytic Protease Inhibitors 	421 
dependent on peptide chain length. Most of the compounds synthesized by 
us were effective inhibitors of porcine pancreatic elastase; Ac-Ala-Ala-Pro-
AIaCH2C1 was the most reactive. The tetrapeptide inhibitors were 10-50 times 
more reactive than the tripeptides. The related serine proteases chymotrypsin 
and trypsin were not significantly inhibited by these peptide chloromethyl 
ketones under identical reaction conditions. Several of our compounds, includ-
ing Ac-Ala-Ala-Ala-AlaCH,C1 and Ac-Ala-Ala-Pro-AlaCH.C1, were also shown 
by Janoff 10 to be effective inhibitors of the human leukocyte elastase. 
We have recently completed a kinetic study of the inhibition of human 
leukocyte elastase by a series of peptide chloromethyl ketones that demonstrates 
that the human leukocyte enzyme is distinct from the porcine pancreatic 
enzyme. Human leukocyte elastase, 85% pure as determined by a gel densi-
tometry scan, which contains one major and two minor elastase isoenzymes, 
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FIGURE 1. Comparison of the reaction pathways for the reaction of elastase with a 
substrate and with a chloromethyl ketone. 
rapidly mixing elastase and inhibitor solutions (0.1 M phosphate, pH 6.5) at 
25° C and allowing the reaction to proceed through at least two half-lives. 
Initial concentrations were: elastase, 10µM; tripeptide inhibitor, 1 mM (or 
tetrapeptide inhibitor, 0.2 mM); CaCl 2 , 0.1 mM; methanol, 5% v/v. Enzyme 
assays were periodically performed with the Boc-Ala-ONp spectrophotometric 
assay at 345 nm.2° Kinetic results for each inhibitor were calculated from the 
equation 
Vhiblb = koiso[E] = k2udI1][E] 
with the aid of a line-fitting computer program and are presented in TABLE 1. 
The second-order rate constant k,, h„d / [I] is suitable only for purposes of 
approximate reactivity comparisons among the inhibitors, because k t,b2d/[f] 
becomes nonlinear with [I] when the latter approaches K 1 , the dissociation 
constant of the enzyme-inhibitor complex.l• 17  Slight problems of reproduci-
bility arose from a lack of enough enzyme for duplicating all inhibition runs, 
but the correlation coefficients for all runs were greater than 0.99. 
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TABLE 1 
IHNIBMON OF HUMAN LEUKOCYTE ELASTASE WITH PEPTIDE CHLOROMETHYL KETONES 
(ELASTASE CONCENTRATION 10 µM, AT PH 6.5, 25° C, 5% METHANOL) 
Inhibitor 	 104 •k.s.a 	 k.s.s/111* 
P. P, Ps P1 (see) (Wiser') 	(rel.) 	(rel.) 
	
Ac-Ala-Ala-AlaCH,C1 	 2.8 t 	2.8 1.0 	9.3 
Ac-Ala-Pro-AlaCH,C1 10.9 10.9 	4.0 14.9 
Ac-Pro-Ala-AlaCI-IsCI 	 0 	0 0 	0 
Z-Gly-Leu-AlaCI-IsCI 20.2 20.2 	7.3 17.6 
Z-Gly-Leu-PheCH.C1 	 0 	0 - 0 	- 
Ac-Ala-Ala-Ala-AlaCI-12C1 2.0 t 9.7 	3.5 167 
Ac-Ala-Ala-Pro-AlaCH 2C1 	 8.7 t 	43.6 15.8 	650 
Ac-Ala-Pro-Ala-AlaCELC1 4.4 22.2 	8.1 0 
Ac-Ala-Ala-Phe-AlaCH :C1 	 2.6 	13.2 4.8 	149 
Ac-Phe-Gly-Ala-LeuCH,CI 1.2 6.0 	2.2 
• Data for porcine pancreatic elastase.' 
t Average of two runs. 
A comparison of the effectiveness of the peptide chloromethyl ketone in-
hibitors, based on their relative k,,,,,„ 1 /1/1 values, leads to several interesting 
relationships between the structure of inhibitors and reactivity toward human 
leukocyte elastase. The tetrapeptides were usually observed to be faster inhibi-
tors than the tripeptides and were run at fivefold lower inhibitor concentrations, 
[I]. Ac-Ala-Ala-Pro-AlaCH„Cl is the best leukocyte elastase inhibitor of the 
series. In general, the tetrapeptides are about three to four times more reactive 
than the tripeptides, which is evidence for the inhibitors' interaction with an 
extended binding site in leukocyte elastase. The P, residue 21 is alanine in 
almost all of the inhibitors, for example, Ac-Ala-Ala-Ala-A/aCH,CI, which 
corresponds to the substrate specificity of elastase for alanine and other amino 
acids with small side chains. If P, is phenylalanine, as in the chymotrypsin 
inhibitor Z-Gly-Leu-PheCH,CI, no leukocyte elastase inhibition is observed, 
whereas if P1 is leucine, as in the potent subtilisin inhibitor Ac-Phe-Gly-Ala-
LeuCH,C1, a small rate of elastase inhibition occurs. In the P, position, proline 
appears to be favored over alanine: k oh.„ 1/[ll for Ac-Ala-Ala-Pro-AlaCH,C1 is 
four to five times larger than that for Ac-Ala-Ala-Ala-AlaCH,C1, and this also 
holds true for the analogous tripeptide pair. A leucine in P, is also favorable, 
as in Z-Gly-Leu-AlaCH,Cl. If the P, residue is proline, as in the tripeptide 
inhibitor Ac-Pro-Ala-AlaCH,C1, leukocyte elastase inhibition is totally blocked, 
but if P, is proline, as in the tetrapeptide inhibitor Ac-Ala-Pro-Ala-AlaCH,Cl, 
elastase inhibition does occur. Ac-Ala-Pro-Ala-AlaCH,C1 is a noninhibitor 
toward porcine pancreatic elastase." , 17 For optimum reactivity, a leukocyte 
elastase inhibitor should contain a P, alanine, a P, proline or leucine, and no 
P3 proline (for tripeptides). 
At this point, it is of interest to examine certain inhibition characteristics 
of human leukocyte elastase, as compared to the more thoroughly studied 
porcine pancreatic elastase. 16 • 17 First, leukocyte elastase reacts less rapidly 
overall with this group of peptide chloromethyl ketones than does pancreatic 
elastase, as indicated by smaller values of k 011„,1 / [I] for inhibition (TABLE 1). 
Second, the increase in reactivity toward inhibitors in going from tripeptides to 
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tetrapeptides is smaller for leukocyte elastase, which fact may indicate differ-
ences in the geometry of the extended binding sites and the effect of tfii 
individual subsites on the catalytic activity of these two enzymes. Third, the 
derived structure-reactivity relationships are generally parallel between the in-
hibitors and the two kinds of elastase. with regard to the structural features 
required for enhancement of elastase inhibition. Finally, Ac-Ala-Ala-Pro-
AlaCH,Cl is the most effective inhibitor tested for both human leukocyte and 
porcine pancreatic elastase. Interestingly, its isomer Ac-Ala-Pro-Ala-AlaCH 2C1 
is a relatively good inhibitor for the leukocyte enzyme but is unable even to 
touch the pancreatic enzyme, which is strong evidence that the leukocyte and 
pancreatic enzymes are distinct entities. 
•Another useful class of inhibitors for serine proteases is the peptide carba-
zates. Carbazates with the appropriate substituents are analogs of amino acids 
in which the a-methine group has been replaced by a nitrogen atom. They 
would thus be expected to acylate elastase in much the same fashion as simple 
synthetic peptide substrates. The carbazoyl enzyme should be considerably 
more stable toward deacylation than is a normal acyl enzyme due to the 
influence of the adjacent nitrogen atom (FIGURE 2). 
The reaction of serine proteases with two carbazates has been previously 
studied. Ethyl 3-acetyl-2-benzylcarbazate is not hydrolyzed by chymotrypsin 
but is, however, a predominantly competitive inhibitor of the enzyme. 22 On the 
other hand, 4-nitrophenyl 3-acetyl-2-benzylcarbazate acylates chymotrypsin and 
trypsin and has been used as an active-site titrant. 22 
We have synthesized two peptide carbazates as potential inhibitors of 
elastase, Ac -Ala -Mec -ONp,/ (Mec = 3-methyl carbazoic acid) with Z-Ala-Ala-
Pro-Mec-ONp,2 (FIGURE 3). Dipeptide / does not react with either pancreatic 
elastases or with human leukocyte elastase, an observation that is not surprising 
in view of the requirement of elastase for an extended peptide chain in a 
substrate 24 or inhibitor.". 22 Tetrapeptide 2 reacted with porcine pancreatic 
elastase (inhibitor to enzyme ratio = 47) at pH 5.0 (0.1 M acetate) or pH 5.8 
(0.1 M citrate) to give a burst of 4-nitrophenol that was complete in less than 
9 sec. Presumably, a carbazoyl enzyme is formed as the other product. The 
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FIGURE 2. Comparison of the structures of an acyl enzyme and a carbazoyl enzyme 
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inactive enzyme thus formed, however, regains activity gradually as the car-
bazoyl group is hydrolyzed slowly from the enzyme (t., at pH 5.0 = 6.2 X 10 2 
sec). Human leukocyte elastase (inhibitor to enzyme ratio = 10 3 ) is also 
rapidly inactivated by Z-Ala-Ala-Pro-Mec-ONp (2) at PH 6.5 (0.1 M phos-
phate). In this case, the reactivation is fairly slow, but a lack of sufficient 
enzyme precluded a careful study of the deacylation reaction. Unfortunately, 
Z-Ala-Ala-Pro-Mec-ON p (2) was not specific for elastase but also acylated 
subtilisin BPN' and chymotrypsin Ay. 
Although Z-Ala-Ala-Pro-Mec-ONp is not a useful inhibitor for elastase, it 
can be used as an active-site titrant. The release of 4-nitrophenol is stoichio-
metric, and the deacylation rate, although not negligible, is much slower than 
the initial acylation. The reagent could not be used, however, in mixtures that 
contained chymotrypsin-like enzymes due to the nonspecificity for the reaction 
of this particular carbazate. We expect to be able to increase the specificity of 
carbazates for elastase by alteration of the extended peptide structure of the 
reagent. In addition, we feel that it is also possible to increase the stability of 
the carbazoyl enzyme in a like manner, which would thus make the parent 






FIGURE 3. Peptide carbazates synthesized as elastase inhibitors. 
carbazoyl derivative of chymotrypsin that has a half-life for deacylation of 
several days. 
In conclusion, we have clearly demonstrated that peptide chloromethyl 
•ketones are valuable active-site-directed inhibitors of human leukocytic and 
porcine pancreatic elastase and that peptide carbazates are useful active-site 
titrants for elastase and are potentially effective inhibitors. At present, several 
investigators have initiated in vivo studies with chloromethyl ketone inhibitors, 
and they are proving useful for elucidating many of the molecular pathways 
by which human leukocyte elastase performs its physiologic and pathologic 
functions. In the future, these or related inhibitors should prove to be useful 
for the treatment of arthritis, pulmonary emphysema, and other diseases that 
involve elastic tissue destruction by elastolytic proteases. 
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1. Introduction 
Recently, an elastolytic protease has been isolated. 
from human polymorphonuelear (PMN) leukocyte 
granule fractions and purified by affinity chromato-
graphy 11]. This human leukocyte elastase is known 
to degrade human lung elastin, arterial walls and base-
ment membrane, digest proteins of bacterial cell walls 
In vitro. induce cellular surface changes correlated with 
lots of growth control, and undergo inhibition by a l - 
anhtryp%in and peptide chloromethyl ketones [2]. A 
growing body of experimental evidence has suggested 
that this elastase may be involved in pathological pro-
cesses associated with elastic tissue damage in pulmo-
nary emphysema and acute arteritis, and with the 
tumor-producing action of cocarcinogenic substances 
[31. Peptide chloromethyl ketones are well-known 
inhibitors of serine proteases which have proved quite 
useful for structural studies, including X-ray crystallo-
graphic investigations, of the active site regions of this 
group of enzymes [4]. A series of alanine tri- and 
tetrapeptide chloromethyl ketone inhibitors was 
synthesized by us and two other groups to probe the 
nature of the extended binding site and catalytic 
activity of porcine pancreatic elastase (EC 3.4.21.11) 
•• j 	related enzymes [5,6]. In this paper we report 
I  
!a study of the inhibition of human leukocyte elas- 
itase by a series of peptide chloromethyl ketones, 
which demonstrates that the human leukocyte enzyme 
is distinct from the porcine pancreatic enzyme. The 
• results also define the structural features necessary 
for an effective inhibitor and may lead to a treatment 
for emphysema and related diseases. 
• To whom requests for reprints should be sent. 
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2. Materials and methods 
Human leukocyte elastase was 85% pure as deter-
mined by a gel densitometry scan and contained one 
major and two minor elastase isoenzymes. Inhibition 
reactions were performed by rapidly mixing elastase 
and inhibitor solutions in 0.1 M phosphate, pH 6.5, 
at 25° C, and allowing the reaction to proceed through 
at least two half-lives. Final concentrations were: 
elastase, 10 pM; tripeptide inhibitor, 1 mM (or tetra-
peptide inhibitor, 0.2 mM); CaC1 2 , 0.1 mM; methanol, 
5% v/v; in a total volume of 0.31 ml. These conditions 
were chosen to minimize the enzyme consumed and 
to facilitate kinetic measurements. Enzyme assays were 
periodically performed on aliquots containing 12.5 pg 
elastase using the BOC-Ala-ONp spectrophotometric 
assay method at 345 nm [7]. Kinetic results for each 
inhibitor were calculated from the equation 
Vinhibition kobscl(E) = k2nd (I) (E) 
with the aid of a line-fitting computer program, and 
are presented in table 1. The second-order rate constant 
kobsd 	is suitable only for purpose of approximate 
reactivity comparisons among the inhibitors, since 
kobscl/(1) becomes non-linear with (I) when (I) becomes 
close to K 1 , the dissociation constant of the enzyme—
inhibitor complex [5]. Due to the small amount of 
enzyme available we were unable to carry out concen-
tration-dependent inhibition studies to determine K 1 
 values. Slight problems of reproducibility arose from 
a lack of enough enzyme for duplicating all inhibition 
runs, but the correlation coefficients for all runs were 
greater than 0.99. 
359 
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• Table 1 
Inhibition of human leukocyte elastase with peptide chloromethyl ketones 
Inhibitor 	 (I) 	104obsd 	1040bsd/(1) kobsd/(I) 
Ps Ps P, 	 (mM) (sec'') 	(M -1 sec" ) (rel.( 
kobsd/(I)* 
(rel.) 
Ac-Ala-Ala-AlaCH2 C1 	1.0 2.8•• 2.8 1.0 1.0 
Ac-Ala-Pro-AlaCH, Cl 1.0 10.9 10.9 4.0 1.6 
Ac-Pro-Ala-AlaCH2 C1 	1.0 0 0 0 0 
Z-Gly -Leu-AlaCH, Cl 1.0 20.2 20.2 7.3, 1.9 
Z -Gly -Le u -PheCH 2 CI 	1.0 0 0 0 - 
Ac-Ala-Ala-Ala-AlaCH2 C1 0.2 2.0** 9.7 3.5 18 
Ac-Ala-Ala-Pro-AlaCH, Cl 0.2 8.7•• 43.6 15.8 71 
Ac-Ala-Pro-Ala-AlaCH, Cl 0.2 4.4 22.2 8.1 0 
Az-Ala-Ala -Phe -AlaCH2 C1 0.2 2.6 13.2 4.8 16 
Ac-Phe-Gly -Ala -LeuCH,Cl 0.2 1.2 6.0 2.2 - 
• Data for porcine pancreatic elastase [51. 
*S Average of two runs. 
Elastase concentration 10 pM, at pH 6.5, 25 °C, 5% methanol. 
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3. Results and discussion 
A comparison of the effectiveness of the peptide 
chloromethyl ketone inhibitors, based on their relative 
kobsdKO values, leads to several interesting relationships 
between the structure of inhibitors and reactivity toward 
human leukocyte elastase. The tetrapeptides were 
usually observed to be faster inhibitors than the tripep-
tides and were run at 5-fold lower inhibitor concentra-
tions (1). Ac-Ala-Ala-Pro-AlaCH2C1 is the best 
leukocyte elastase inhibitor of the series. In general the 
tetrapeptides are about 3 to 4 times more reactive than 
the tripeptides, which is evidence for the inhibitors' 
interaction with an extended binding site in leukocyte 
elastase. The P 1 residue [8] is alanine in almost all of 
the inhibitors, e.g. Ac-Ala-Ala-Ala -A la cH2a, 
corresponding to the substrate specificity of elastase 
for alanine and other amino acids with small side 
chains. If P 1 is phenylalanine, as in the chymotrypsin 
inhibitor Z-Gly-Leu-PheCH2 CI, no leukocyte elastase 
inhibition is observed, whereas if P 1 is leucine, as in the 
potent subtilisin inhibitor Ac-Phe-Gly-Ala-LeuCH2C1, 
a small rate of elastase inhibition takes place. In the 
P2 position, proline appears to be favored over alanine: 
kobsd KI) for Ac-Ala-Ala -Pro -AlaCH2 CI is 4 to 5 
times larger than for Ac-Ala-Ala -A la -CH 2 Cl, and this 
also holds true for the analogous tripeptide pair. A 
leucine in P2 is also favorable as in Z-Gly-Leu-
AlaCH2 C1, but a phenylalanine in P2 is little better 
than alanine: compare Ac-Ala-Ala -Phe-AlaCH 2 CI 
with Ac-Ala-Ala -Ala -AlaCH2 C1. Thus human 
leukocyte elastase may possibly exhibit a weak secon-
dary specificity for inhibitors with P2 residues possess-
ing medium-sized alkyl side chains (4). If the P3 residue 
is proline as in the tripeptide inhibitor Ac-Pro-Ala-
Ala-CH2C1, no inhibition of leukocyte elastase is 
observed. But if P3 is proline as in the tetrapeptide 
inhibitor Ac-Ala -Pro -Ala-Ala-CH 2 C1, elastase 
inhibition does occur. Ac-Ala -Pro -Ala-Ala-CH2 CI 
is a non-inhibitor toward porcine pancreatic elastase 
[5]. In the P4 position a large hydrophobic group, 
e.g. phenyl, appears to be beneficial although further 
studies will be necessary for verification. This could 
explain the higher than expected activity of Z -Gly - 
Leu-AlaCH2 Cl and Ac -Phe-Gly-Ala-LeuCH 2 a, 
both of which possess a benzyl side chain at P 4 , toward 
leukocyte elastase. For optimum reactivity, a leukocyte 
elastase inhibitor should contain a P I alanine, a P2 
proline or leucine, no P3 proline (in the case of tri-
peptides), and possibly a P4 phenylalanine. 
At this point, it is of interest to examine certain 
inhibition characteristics of human leukocyte elastase 
as compared to the more thoroughly studied porcine 
pancreatic elastase [5]. First of all, leukocyte elastase 
reacts less rapidly overall with this group of peptide 
chloromethyl ketones than does pancreatic elastase. 
as indicated by smaller values of k obsd 41) for inhibi-
tion. Secondly, the increase in reactivity toward inln- 
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bitors in going from tripeptides to tetrapeptides is 
smaller in the case of leukocyte elastase, which may 
indicate differences in the geometry of the extended 
binding sites and the effect of the individual subsites 
on the catalytic activity of these two enzymes. Thirdly, 
the derived structure—reactivity relationships are 
generally parallel between the inhibitors and the two 
kinds of elastase, with regard to the structural features 
required for enhancement of elastase inhibition. 
Finally, Ac—Ala—Ala—Pro—AlaCH 2 C1 is the most 
effective inhibitor tested for both human leukocyte 
and porcine pancreatic elastase. Interestingly, its isomer 
Ac—Ala—Pro—Ala—AlaCH 2 C1 is a relatively good inhi-
bitor for the leukocyte enzyme but is not effective 
to touch the pancreatic enzyme, which is strong 
evidence that the leukocyte and pancreatic enzymes 
are distinct entities. 
In conclusion, this initial kinetic study of human 
leukocyte elastase clearly demonstrates the value of 
peptide chloromethyl ketones as active-site directed 
inhibitors for this enzyme in providing structure—reac-
tivity correlations. At present a number of investiga- 	- 
tors have begun in vivo enzymatic studies with these 
inhibitors and they should prove useful for elucidating 
many of the molecular pathways by which human 
leukocyte elastase carries out its physiological and 
pathological functions. 
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I. Summary.  
Pulmonary emphysema is currently thought to result from the un-
inhibited proteolysis of lung tissue by elastase and other proteases. 
Synthetic inhibitors capable of specifically inhibiting elastase would 
be expected to be useful reagents both for the treatment of emphysema 
and for the study of the biological function of elastalytic enzymes. 
Human leukocyte elastase is irreversibly inhibited by peptide 
chloromethyl ketones. The peptide chloromethyl ketones Ac-Ala-Ala-Ala-
AlaCH2C1 and Ac-Ala-Ala-Pro-AlaCH2
C1 were synthesized and distributed 
to over 30 other investigators for use in the study of this enzyme 
and its role in lung disease. Studies of the rate of inhibition of 
human leukocyte elastase by chloromethyl ketones led to the design and 
synthesis of Ac-Ala-Ala-Pro-Va1CH2C1 and Ac-Ala-Ala-Pro-lleCH2C1 which 
are 49 and 40 fold respectively more effective inhibitors than 
Ac-Ala-Ala-Pro-AlaCH2
C1. A number of papers have already been published 
in which these peptide chloromethyl ketones have been utilized. 
Peptide carbazates have been studied as possible elastase inhibitors. 
Ac-Ala-Ala-Mec-ONp (Mec = -NHN(CH3)C0-) acylates elastase within a few 
seconds with concurrent inhibition of the enzyme. However, the acylation 
is reversible and the enzyme regains activity in 0.25 to 1 hr. The 
carbazate is a useful reagent for titrating elastase and has been dis-
tributed to several other investigators. 
II. Introduction  
Pulmonary emphysema is currently thought to result from the un-
inhibited proteolysis of lung tissue by elastase and related neutral 
proteases derived from leukocytes, alveolar macrophages or other cellular 
sources (Mittman, 1972). During infection or inflammation, the 
-4- 
normal lung is protected-from proteolytic digestion by the serum pro-
tease inhibitor , a l -antitrypsin. Individuals with an inherited deficiency 
of a
1 -antitrypsin often develop emphysema at an early age. In addition 
to a
1 -antripsin deficiency, emphysema is also probably related to the 
rate of release of proteases in lung tissue either from exogenous sources 
(e.g. bacterial infection) or by the stimulation of normal cellular 
protease producing pathways by environmental factors (smoking, air pol-
lution, etc.). Thus, individuals with normal a l -antitrypsin levels, 
but with high rates of protease production are also susceptible to lung 
disease. 
Synthetic inhibitors capable of specifically inhibiting elastase 
would be expected to be useful reagents both for the treatment of 
emphysema and related diseases and for the study of the biological 
function of elastolytic enzymes. Such compounds could potentially be 
utilized to replace a l -antitrypsin in individuals with an inherited 
deficiency. They might also be useful for the protection of individuals 
with high rates of protease release into lung tissue. Since emphysema 
is characterized by the gradual evolution of lesions in the lung due 
to proteolytic destruction of elastin in the alveolar structure, elastase 
inhibitors should also be capable of arresting the further development 
of the disease in individuals already inflicted with emphysema. 
This contract dealt with the synthesis of peptide chloromethyl 
ketones which we have shown to be highly reactive and specific elastase 
inhibitors (Powers and Tuhy, 1972 and 1973; Tuhy and Powers, 1975) and with the 
design and synthesis of other elastase inhibitors with a variety of 
functional groups. Many of our elastase inhibitors have already been 
used or are currently being used by other investigators engaged in the 
study of the role of proteolytic enzymes in pathological lung disease. 
-5- 
III. Goals 






2. Study the inhibition of leukocyte elastase with a series of 
peptide chloromethyl ketones in order to optimize the inhibitor structure. 
3. Synthesize other elastase inhibitors such as peptide carbazates 
with more desirable properties such as solubility, hydrophobicity, 
reactivity and specificity. 
4. Distribute inhibitors including carbazates to investigators who 
have submitted justified requests to the staff of the Division of Lung 
Diseases. 
IV. Background  
Elastase. Elastase is a serine protease homologous to chymotrypsin and 
trypsin which digests elastin, the flexible protein component of lung 
and elastic connective tissue. Elastase activity has been found in a 
variety of locations, including human pancreatic extracts (Hartley and 
Shotton, 1971), human peripheral blood polymorphonuclear leukocytes 
and alveolar macrophages (Janoff, 1972). 
Pancreatic porcine elastase has been extensively studied due to 
its ready availability. Studies of its substrate specificity using 
N-benzyloxycarbonylamino acid 2-nitrophenyl esters (Geneste and Bender, 
1969), N•benzoylamino acid methyl esters (Kaplan, et. al., 1970), 
oxidized insulin A and B chains (Narayanian and Awar, 1969), and ribo-
nuclease S peptide (Atlas, et. al., 1970) have shown that porcine 
pancreatic elastase cleaves most readily peptide bonds C terminal to 
alanine residues. This is consistent with the observation that elastin, 
elastase's normal substrate, contains a high percentage of alanine, 
glycine and proline. More recent work with synthetic peptides has 
shown that the rate of elastase hydrolysis is strongly dependent on 
-6- 
chain length (Atlas, et; al., 1970; Atlas and Berger, 1972; Thompson 
and Blout, 1970, 1973b) with a substantial increase occuring on going 
from tripeptide to tetrapeptide substrates (Thompson and Blout, 1973b). 
These results indicate that elastase, like the serine proteases chymo-
trypsin (Segal, et. al., 1971 a and b) and subtilisin (Kraut, et. al., 
1971; Robertus, et. al., 1972), contains an extended substrate binding 
site. 
The three dimensional structure of porcine pancreatic elastase has 
been determined by X-ray crystallography (Hartley and Shotton, 1971; 
Shotton, et. al., 1972). The catalytic site consists of a charge relay 
system (Figure 1) composed of an aspartic acid residue, a serine residue 
(Ser-188) and the imidazole ring of a histidine residue (His-45). During 
elastase catalyzed hydrolysis of a peptide substrate, Ser-188 is acylated 
by the acyl portion of the peptide bond that is cleaved (see Figure 2). 
A shallow pocket is located on the surface of the enzyme adjacent to the 
catalytic residues. This region of the enzyme is responsible for the 
observed specificity of elastase since only the side chains of certain 
amino acid residues (e.g., alanine) can fit into this pocket. Crystallo-
graphic experiments to elucidate the nature of the extended substrate 
binding region of porcine pancreatic elastase are in progress (D. M. 
Shotton, personal communication), although I expect it to be very 
similar to that observed in the homologous serine proteases, chymotrypsin 
and subtilisin. 
Knowledge of the leukocyte elastase(s) is much more limited. 
However, the few experiments that have been carried out with the leukocyte 
elastase have left little doubt concerning the essential similarity of the 
pancreatic enzyme and the leukocyte elastase. For example, the leukocyte 
enzyme can be assayed using the same synthetic substrates Boc-Ala-ONp 
and Ac-Ala-Ala-Ala-OMe (Janoff, 1969; Janoff and Basch, 1971) that were 
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developed to assay porcine pancreatic elastase. The pH optimiums of the 
two enzymes are similar (Janoff and Scherer, 1968). The human granulocyte 
elastase is inhibited by diisopropylphosphoro fluoridate, a reaction 
characteristic of serine proteases, and by serum al -antitrypsin (Janoff, 
1972 a). The two enzymes differ in certain respects. The pancreatic 
enzyme is inhibited by soybean trypsin inhibitor, salivary kallikrein 
inhibitor, and by high salt concentrations while the leukocyte enzyme 
is not. Higher concentrations of serum are required to inhibit the 
leukocyte enzyme (Janoff, 1972b). Although the situation at present is 
complicated by the separation of the leukocyte enzyme into three dis-
tinct isozymes (Janoff, 1973; Sweetman, et. al., 1973), it would appear 
logical to assume that the leukocyte elastase(s) and pancreatic elastase 
are members of the same family of enzymes. The differences in their 
chemical behavior are probably due to differences in their amino acid 
sequences at sites removed from the catalytic site. 
Elastase Inhibitors. Synthetic inhibitors with a variety of func-
tional groups have been shown to react stoichiometrically with elastase. 
These include reagents such as diisoPropylphosphorofluoridate, 
phenyl diethyl phosphate, tosyl fluoride and phenyl methane sulfonyl 
fluoride, all of which react with the strongly nucleophilic active site 
serine residue of serine proteases, including Ser-188 of elastase 
(Hartley and Shotton, 1971). Brown and Wold (1973 a,b) have recently 
shown that n-butyl isocyanate also inhibits elastase by reaction at 
Ser-188. This reagent was not specific for elastase since in addition 
it inhibited chymotrypsin. Stoichiometric alkylation of the y-carboxyl 
group of a glutamic acid residue, tentatively identified as Glu-6, by 
1-bromo-4-(2,4-dinitrophenyl) butane-2-one inhibits porcine pancreatic 
elastase (Visser, et. al., 1971). However, this reagent was incapable 
of inhibiting the human leukocyte elastase (Janoff, 1969). Since Glu-6 
-9- 
is not near the active site in porcine pancreatic elastase, a precise 
explanation for this inhibition reaction is unavailable. 
V. Peptide Chloromethyl Ketones 
Rationale. A few years ago, it appeared to us that peptide chloro-
methyl ketones were likely candidates for use as elastase inhibitors. 
These compounds are relatives of Tos-Phe-CH 2C1 (TPCK) and Tos-LysCH2C1 
(TLCK), the active site specific inhibitors of chymotrypsin and trypsin 
developed by Elliott Shaw and his coworkers (Shaw, 1970). The crystallo-
graphic determinations of the binding modes of peptide chloromethyl 
ketones to chymotrypsin A (Segal et. al., 1971 a,b) and to subtilisin 
BPN' (Kraut, et. al., 1971; Robertus, et. al., 1972) have provided 
revealing insights into the interactions of inhibitors with these serine 
protease:. The inhibitors are bound to the enzyme via a covalent linkage 
between the imidazole ring of the active site histidine residue and the 
methylene group of the chloromethyl ketone moiety (see Figure 3 for a 
comparison of the reaction of a chloromethyl ketone and a substrate with 
a serine protease). The peptide chain of an extended inhibitor and a 
section of three residues of the backbone of chymotrypsin and subtilisin 
form an antiparallel --sheet structure. In addition, the rates of in-
activation of chymotrypsin Aa (Kurachi, et. al., 1973) and subtilisin BPN' 
(J. C. Powers and J. T. Tippett, unpublished observations) by chloro-
methyl ketones in solution are dependent upon the interactions between 
the enzyme and inhibitor both in the region of the primary specificity 
site and at subsites far removed from the catalytic site. 
Synthesis of a series of peptide chloromethyl ketones with an 
alanine as the P
1 
residue (see Figure 4 for the nomenclature) and study 
of their reactivity with porcine pancreatic elastase produced a series 
of effective elastase inhibitors (Powers and Tuhy, 1972 and 1973, see 
also Thompson and Blout, 1973a for similar independent studies). The 
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tetrapeptide chloromethyl ketone, Ac-Ala-Ala-Pro-A1aCH 2C1, was the 
most effective inhibitor in the series. The inhibitors were very 
specific for elastase since the homologous serine proteases, chymo-
trypsin and trypsin, were not significantly inhibited under identical 
conditions. The tetrapeptide inhibitors were 10 to 80 times more 




I was due both to the better binding of the inhibitor to elastase 
(the KI of Ac-Ala-Ala-Ala-AlaCH2C1 is three times lower than that of 
Ac-Ala-Ala-AlaCH
2C1) and to the increased rate of reaction within the 
bound complex (the k 3 for Ac-Ala-Ala-Ala-AlaCH 2C1 is three times higher 
than that for Ac-Ala-Ala-AlaCH2C1). Since peptide substrates exhibit 
a similar reactivity difference between tripeptides and tetrapeptides, 
both inhibitors and substrates are probably interacting with the same 
extended binding site in elastase. Proline and/or leucine are the 
preferred residues at the P 2 site of an inhibitor (e.g., as in 
Ac-Ala-Ala-Pro-AlaCH2C1 or Z-Gly-Leu-AlaCH2C1), Pro at the P 3 site 
(as in Ac-Pro-Ala-AlaCH2C1 or Ac-Ala-Pro-Ala-AlaCH 2C1) renders an 
inhibitor incapable of inhibiting elastase. In summary, a series of 
reactive and specific elastase inhibitors had been prepared and had 
been used to partially map the individual subsite requirements in order 
to obtain the optimium inhibitor structure. 
Synthetic Results. The first goal of this contract was to prepare 
large quantities of Ac-Ala-Ala-Ala-AlaCH 2C1 and Ac-Ala-Ala-Pro-AlaCH 2C1 
for distribution to other investigators. This was accomplished using 
the synthetic scheme listed in Fig. 5 and experimental details are 
published in Powers and Tuhy (1973). 
Distribution. As of October 1975, a total of 37 separate shipments 
of chloromethyl ketones to almost that many different investigators have 
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containing detailed information with literature references was mailed 
at the same time. In this way, the investigator would be expecting 
the shipment and would be alerted if it did not arrive. In all cases 
except one or two, the shipment arrived safely. In the others, a 
second shipment was made. A list of the investigators and the amounts 
inhbititors sent are listed in Table I. At this time, we have on hand 
approximately 7 g of Ac-Ala-Ala-Ala-AlaCH 2C1 and 5.75 g of Ac-Ala-Ala-
Pro-AlaCH2
Cl and have shipped 0.94 and 1.28 g respectively. 
Inhibition of Human Leukocyte Elastase. The second goal of this 
contract was to study the inhibition of leukocyte elastase with a series 
of peptide chloromethyl ketones in order to optimize the inhibitor 
structure. This has been accomplished using enzyme graciously supplied 
by Aaron Janoff (Stoney Brook, N.Y.) and is published (Tuhy and Powers, 
1975). A copy of that paper is attached as an appendix. 
The results indicate that leukocyte elastase reacts less rapidly 
overall with this group of peptide chloromethyl ketones than does 
pancreatic elastase, as indicated by smaller values of kobsd/[I] for 
inhibition. The increase in reactivity toward inhibitors in going 
from tripeptides to tetrapeptides is smaller in the case of leukocyte 
elastase, which may indicate differences in the geometry of the extended 
binding sites and the effect of the individual subsites on the catalytic 
activity of these two enzymes. The most effective inhibitor for both 
the human leukocyte and porcine elastase in this series of compounds 
is Ac-Ala-Ala-Pro-AlaCH2
C1. Interestingly, its isomer Ac-Ala-Pro-Ala-
AlaCH2
Cl is a relatively good inhibitor for the leukocyte enzyme but 
is not effective toward the pancreatic enzyme, which is strong 
evidence that the leukocyte and pancreatic enzymes are distinct entities. 
A series of inhibitors with varied P 1 
residues was recently 
synthesized and their rates of inhibition measured with the human leu- 
kocyte elastase. From the following data, it can be seen that both 
Ac-Ala-Ala•Pro-ValCH
2
Cl and Ac-Ala-Ala-Pro-IleCH 2
C1 are more effective 
inhibitors than Ac-Ala-Ala-Pro-AlaCH 2
C1. 
Inhibitor Relative inhibition rate 
Ac-Ala-Ala -Pro-ValCH2Cl 
49 
Ac-Ala-Ala -Pro-IleCH2  Cl 
40 
Ac-Ala-Ala. -Pro-AlaCH 2C1 
1 
Ac-Ala-Ala-Pro-ThrCH2  Cl 
0.5 
We have synthesized 2 g of Ac-Ala-Ala-Pro-Va1CH 2C1 for distribution, 
but at present have received no requests for this inhibitor. 
Published Studies of other Investigators. Since our initial report of 
the synthesis of alanyl peptide chloromethyl ketones and their effect-
iveness in inhibiting porcine elastase, other elastolytic enzymes have 
also been shown to be inhibited by these compounds. The digestion of 
human lung tissue and rat aortic tissue by porcine pancreatic elastase 
or human polymorphonuclear leukocytic elastase is totally inhibited 
by Ac-Ala-Ala-AlaCH2C1 in vitro (Janoff, 1972). Mosser, et. al., (1973) 
have recently shown that preincubation of human leukocyte lysosomes with 
Ac-Alai-Ala-Pro-AlaCH2
C1 depresses the ability of the lysosomal prepara-
tion to promote agglutinability by concanavalin A in mouse fibroblasts. 
In addition, Ac-Ala-Ala-AlaCH2C1 has proven useful in the location of 
elastolytic enzymes on disc electrophoresis zymograms; it inhibits the 
esterolytic activity of three major neutrophil esterases from human 
polymorphonuclear granules which exhibit elastase-like behavior 
(Sweetman, et. al., 1973). The chloromethyl ketone inhibitors were used 
in studies which suggest that PMN elastase plays a role in the digestion 
of certain bacteria (Janoff and Blondin, 1973 and 1974). The digestion of 




#1 John A. Pierce, M.D. 
Pulmonary Disease Division 
Barnes & Wohl Hospitals 
660 South Euclid Avenue Box 8121 
St. Louis, Missouri 	63110 50 mg 	9/13/74 
2 Irwin E. Liener, Ph.D. 
J Department of Biochemistry 
140 Gortner Laboratory 
University of Minnesota 
St. Paul, Minnesota 	55101 10 mg 12 mg 9/13/74 
3 James 0. Harris, M.D. 
Pulmonary Section 
Veterans Administration Hospital 
Gainesville, Florida 	32601 11 mg 12 mg 9/13/74 
4 Morton Galdston, M.D. 
New York University Medical Center 
School of Medicine 
550 First Avenue 
New York, New York 	10016 54 mg 52 mg 9/13/74 
5 Jerome Klienerman, M.D. 
Saint Luke's Hospital 
11311 Shaker Boulevard 
Cleveland, Ohio 	44104 152 mg 9/13/74 
6 Arthur Dannenburg, Ph.D. 
Dept. Enviromental Medicine 
School of Hygiene & Public Health 
The Johns Hopkins University 
615 North Wolfe Street 
Baltimore, Maryland 	21205 26 mg 9/13/74 
7 Robert Senior, M.D. 
The Jewish Hospital of St. Louis 
216 South Kingshighway 
St. Louis, Missouri 	63110 30 mg 9/13/74 
8 Virginia Richmond, M.D. 
Virginia Mason Research Center 
1000 Seneca Street 
Seattle, Washington 	98101 52 mg 53 mg 9/13/74 
9 Ines Mandl, Ph.D. 
Department of Obsterics & Gynecology 
College of Physicans & Surgeons 
Columbia University 
630 West 168th Street 
New York, New York 	10032 53 mg 51 mg 9/13/74 
TABLE I. 	(Con't) 
10 	Daniel Menz41, M.D. 
Department of Physiology i Pharmaiology 
Duke University Medical Center 
Durham, North Carolina 	27710 	54 mg 
11 	Robert I. Lehrner, M.D. 
Department of Medicine 
105 mg 9/13/74 
Center for Health Sciences 
VCLA 
Los Angeles, California 	90024 11 mg 14 mg 9/19/74 
12 S. S. Spicer, 	Ph.D. 
Department of Pathology 
Institute of Pathology 
Medical University of South Carolina 
80 Barre Street 
Charleston, South Carolina 	29401 10 mg 9/13/74 
13 Harold Resnick, M.D. 
National Institute for Occupational 
Safety & Health 
P.O. Box 4292 
Morgantown, West Virginia 	26505 5 mg 9 mg 9/13/74 
14 V. B. Hatcher, Ph.D. 
Montefiore Hospital & Medical Center 
111 East 210th Street 
Bronx, New York 	10467 11 mg 11 mg 9/13/74 
15 A. Myron Johnson, Ph.D. 
Department of Pediatrics 
School of Medicine 
University of North Carolina 
Chapel Hill, North Carolina 	27514 7 mg 8 mg 9/13/74 
16 Thomas Kravis, M.D. 
Experimental Immunology Division 
Clinical Medical Sciences Department 
Naval Medical Research Institute 
National Naval Medical Center 
Bethesda, Maryland 	20014 12 mg 9/19/74 
17 Kjell Ohlsson, M.D. 
Department of Surgery 
University of Lund 
Malmo General Hospital 
214 	01 	Malmo 	Sweden 133 mg 11/74 
18 Phillip Stone, Ph.D. 
Department of Biochemistry 
Boston University Medical Center 
School of Medicine 
80 East Concord Street 
Boston, Massachusetts 02118 	207 mg 12/31/74 
TABLE I (Con't) 
19 Chin C. Huang, M.D. 
Biochemistry Research Department 
Armour Pharmaceutical Company 
Box 511 
Kankakee, Illinois 60901 
\-) 20 Marc H. Dresden, Ph.D. 
Department of Biochemistry 
Baylor College of Medicine 
Texas Medical Center 
Houston, Texas 77025 
21 Isaac Ginsburg, Ph.D. 
Department of Oral Biology 
The Hebrew University 
Hadassah Medical School 
P.O. Box 1172 
Jerusalem, Israel 
22 Larry Wahl, Ph.D. 
Laboratory of Developmental Biology 
& Anomalies 
National Institute of Dental Research 
Bethesda, Maryland 20014 
23 Aaron Janoff, Ph.D. 
Department of Pathology 
Health Sciences Center 
State University of New York, Stony Brook 
Stony Brook, New York 11790 	100 mg 
24 Yoshiko Narahashi, Ph.D. 
Polymer Chemistry Lab 
The Institute of Physical 
& Chemical Research 
2-1, Hirosawa, Wakoshi 
Saitama, JAPAN 
25 Victor Hatcher, Ph.D. 
Montefiore Hospital & Medical Center 
Albert Einstein College of Medicine 
111 East 210th Street 
Bronx, New York 10467 
26 Robert A. Clark, M.D. 
School of Medicine 
Department of Medicine RM-16 
University of Washington 
Seattle, Washington 98195 	 53 mg 
(Second shipment) 53 mg 
27 J. C. Taylor, Ph.D. 
Scripps Clinic (t Research Foundation 
Department of Microbiology 
476 Prospect Street 
La Jolla, California 92037 
10 mg 12/31/74 
10 mg 2/19/75 
5.1 mg 6/1/75 
10 mg 2/19/75 
10 mg 4/4/75 
100 mg 4/15/75 
50 mg 6/2/75 
50.mg 9/16/75 
51 mg, 6/20/75 
11 mg 	 18 mg 4/24/75 
(and 11 mg Ac-Ala-Ala-AlaCH 2C1) 
22 mg 	 21 mg 5/8/75 
TABLE I. 	(Conit) 
28 	Bruce Sloan, Ph.D. 
Pulmonary Disease Section 
Albert Einstein Medical Center 
York & Tabor Roads 
Philadelphia, Pennsylvania 	19141 102 mg 100 mg 6/20/75 
29 Edward Bittar, M.D. 
Section 6205 
Memorial Sloan Kettering 
Cancer Center 
1275 York Avenue 
New York, New York 	10021 12.1 mg 10 mg 8/25/75 
30 John Gleisner, Ph.D. 
Virginia Mason Research Center 
1000 Seneca Street 
Seattle, Washington 	98101 11 mg 10 mg 8/26/75 
31 John Aronson, Ph.D. 
Department of Medicine 
Hospital of the University 
of Pennsylvania 
3400 Spruce Street 
Philadelphia, Pennsylvania 	19104 5.6 mg 8/26/75 
32 Alvin Davis, M.D. 
Infectious Disease Section 
Veterans Administration Hospital 
5901 East 7th Street 
Long Beach, California 	90801 6.5 mg 6.6 mg 9/16/75 
33 Jerry Dolovich, M.D. 
Department of Pediatrics 
McMaster University 
1200 Main Street, West 
Hamilton, Ontario 
CANADA, L8S 	4J9 6.3 mg 8/26/75 
34 A. C. Allison, M.D. 
Clinical Research Centre 
Division of. Cell Pathology 
Watford Road 
Harrow, Middlesex England 
HA' 	3UJ 61 mg 50 mg 9/16/75 
35 Friedrich Kueppers, M.D. 
Thoracic Diseases & Internal Medicine 
Mayo Clinic 
Rochester, Minnesota 	55901 50 mg 9/29/75 
936.6 mg 	 1283.6 mg 
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articular cartilage proteglycan by granules and human neutrophil elastase 
• 
is stopped by treatment with Ac-Ala-Ala-AlaCH 2C1 and Ac-Ala-Ala-Pro-AlaCH2C1 
(Malemud and Janoff, 1975). 
A human pancreatic enzyme, protease E, is inhibited by a number of 
alanyl chloromethyl ketones ,(Mallory and Travis, 1975). Cathepsin B was 
also inhibited by Ac-Ala-Ala-Ala-AlaCH 2C1 and Ac-Ala-Ala-Pro-AlaCH2C1 
(Barrett, 1973; Starkey and Barrett, 1973; Burleigh et. al., 1974). 
VI. Peptide Carbazates. 
Rationale. Peptide carbazates can be considered to be analogs of 
peptide substrates in which the a-carbon atom of the P 1 
residue has been 
replaced by a nitrogen atom (see Figure 6). They would thus be expected 
to acylate a serine protease with the appropriate specificity in much the 
same fashion as simple synthetic substrates. The acylated enzymes should 
be considerably more stable toward deacylation than a normal "acyl enzyme" 
due to the influence of the adjacent nitrogen atom. The carbazate, 
p:nitrophenyl N2-acetyl-N 1 -benzylcarbazate, has been used as an active 
site titrant for chymotrypsin (Elmore and Smyth, 1968). The carbazate 
Ac-Ala-NHN(CH2C6H5
)C0-0Np has been prepared and shown to acylate chymo-
trypsin irreversibly (half life for reactivation >52 hrs) (Powers and 
Carroll, unpublished results). 
The third goal of this contract was to synthesize peptide carbazates 
as elastase inhibitors and study their effectiveness. 
Synthetic Results and Distribution. Three carbazates have been synthe-
sized by the methods outlined in Fig. 7. One carbazate, Ac-Ala-Ala-Mec-ONp, 
has been prepared in sufficient quantities (ca. 1 g) for distribution. At 
present, this carbazate has been sent to the following three investigators: 
Dr. Aaron Janoff 
Department of Pathology 
Health Sciences Center 
State University of New York, Stony Brook 
Stony Brook, New York 11790 51 mg 7/18/75 
A- 
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5i■mi lady 
S n -1-1 Pepi; d. Cud oecuties , 
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Dr. A. J. Barrett 
Strangeways Research Laboratory ' 
Wort's Causeway 
Cambridge. CB1 4RN 
Dr. Ohlsson 
Department of Surgery 
University of Lund 
Malmo General Hosp,ital 
214 01 Malmo Sweden 
Will be mailed shortly 
Will be mailed shortly 
Inhibition of Human Leukocyte Elastase. The dipeptide carbazate 
Ac-Ala-Mec-ONp(Mec = 2-methyl carbazoic acid) does not react with human 
leukocyte elastase, an observation that is not suprising in view of the 
requirement of elastase for an extended peptide chain in a substrate or 
inhibitor. Both the tetrapeptide and the tripeptide carbazates react 
with elastase at pH 6.0 to give a burst of 4-nitrophenol within a few 
seconds. Presumably, a carbazyl enzyme is formed as the other product. 
The inactive enzyme thus formed, however, regains activity gradually as 
the carbazyl group is hydrolyzed slowly from the enzyme. The rates of 
reactivation have not yet been accurately measured, but the t1/2 is on 
the order of 15 min at pH 6.0. The reactivation rate does not seem to 
be affected by more than twofold when the structure of the carbazate is 
altered. Thus, it appears carbazates will be useful only as temporary 
inhibitors of human leukocyte elastase. 
Although Ac-Ala-Ala-Mec-ONp is not a useful inhibitor, it can be 
used as an active site titrant. The release of 4-nitrophenol is stoichio-
metric, and the deacylation rate, although not negligible, is much slower 
than the initial acylation. Although Ac-Ala-Ala-Mec-ONp does react 
with chymotrypsin, it can be used under the appropriate conditions to 
titrate elastase in the presence of chymotrypsin. 
VII. Results and Conclusions  
In conclusion, we have clearly demonstrated that peptide chloromethyl 
ketones are valuable active-site directed inhibitors of human leukocyte 
elastase and that peptide carbazates are useful active-site titrants 
for elastase. We have distributed these inhibitors to thirty-five 
other investigators, several of which have initiated in vivo studies 
with chloromethyl ketone inhibitors. They have proved to be useful for 
elucidating many of the molecular pathways by which human leukocyte 
elastase performs its physiologic and pathologic functions. In the 
future, these or related inhibitors should prove to be useful for the 
treatment of pulmonary emphysema, arthritis and other diseases that 
involve elastic tissue destruction by elastolytic proteases. 
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